Caricamento...
Benefit assessment in Germany: implications for price discounts
BACKGROUND: The AMNOG regulation, introduced in 2011 in Germany, changed the game for new drugs. Now, the industry is required to submit a dossier to the GBA (the central decision body in the German sickness fund system) to show additional benefit. After granting the magnitude of the additional bene...
Salvato in:
| Pubblicato in: | Health Econ Rev |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Berlin Heidelberg
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4970987/ https://ncbi.nlm.nih.gov/pubmed/27485438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13561-016-0109-3 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|